TOPPAN Holdings Launches US Subsidiary to Advance Personalized Cancer Medicine Using 3D Cell Culture Technology
Key Insights
TOPPAN Holdings (search) has established TOPPAN Global Medical Healthcare Inc. (search) in Houston's Texas Medical Center (search) to advance personalized cancer medicine using its proprietary invivoid™ (search) 3D cell culture technology.
The new company will accelerate clinical validation studies with UT MD Anderson Cancer Center and work toward obtaining CAP/CLIA certification for cancer testing applications.
The invivoid™ (search) technology can establish cancer organoids from patient biopsy tissue within days, enabling rapid drug screening to identify optimal treatments for individual patients.
TOPPAN Holdings (search) Inc. has established a new subsidiary, TOPPAN Global Medical Healthcare Inc. (search), in Houston, Texas, to accelerate the development and implementation of personalized cancer medicine using its proprietary invivoid™ (search) 3D cell culture technology. The March 2026 launch positions the Japanese company to capitalize on the growing global demand for precision oncology solutions.
Strategic Location in Texas Medical Center
The new company is headquartered in the TMC3 Collaborative Building within Helix Park, a commercial life sciences and innovation hub in the Texas Medical Center (search). This strategic location provides direct access to TMC's extensive network of cancer research facilities, clinical institutions, and patient populations. The facility represents a US$2.0 million investment and will be led by President and CEO Shiro Kitano.
Building on MD Anderson Partnership
The establishment follows TOPPAN Holdings (search)' July 2025 strategic alliance with The University of Texas MD Anderson Cancer Center to co-develop clinical tools for evaluating treatment efficacy using patient-derived samples. The new subsidiary will serve as the operational headquarters to manage collaborations with local medical institutions and pharmaceutical companies across the United States healthcare market.
Three-Pronged Business Strategy
TOPPAN Global Medical Healthcare will focus on three key objectives. First, the company aims to accelerate clinical validation by deepening joint research with UT MD Anderson to expedite clinical validation studies across multiple cancer types while working toward obtaining College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certification.
Second, the subsidiary will expand drug discovery support by providing major US pharmaceutical companies with efficient drug screening environments utilizing the invivoid™ (search) platform. Third, the company plans to establish a global network by leveraging Houston's position as a medical innovation hub to incorporate cutting-edge knowledge, top-tier talent, and research institution connections into worldwide business development.
Advanced 3D Cell Culture Technology
The invivoid™ (search) technology, developed through joint research with the University of Osaka (search), enables rapid creation of artificial tissues that closely mimic living organisms. The platform can establish "cancer organoids" or mini-cancers from minute amounts of patient biopsy tissue within just a few days, representing a significant advancement in speed compared to traditional methods.
The technology's key advantages include optimal treatment selection capabilities, allowing clinicians to test multiple drug types before actual administration to identify the most effective treatment for each patient. This approach helps avoid unnecessary side effects and treatment delays. The platform also demonstrates high reproducibility by accurately reproducing complex microenvironments found within the human body using specialized biomaterials and coating agents.
Market Positioning and Future Outlook
TOPPAN Holdings (search) has positioned the medical and healthcare field as a core pillar of growth and plans to continue aggressive global business expansion. Through the new subsidiary, the company aims to build a track record of clinical success in the United States and contribute to delivering optimal medical care to every cancer patient.
The establishment of TOPPAN Global Medical Healthcare represents a strategic move to address the rapidly growing global demand for personalized medicine in cancer treatment, which focuses on selecting the most effective therapies and drugs for individual patients based on their specific tumor characteristics and genetic profiles.